Result : 11

The history of Hodgkin lymphoma

Hodgkin lymphoma was initially considered to be caused by infectious agents. The Hodgkin and Reed-Sternberg tumor cells are derived from mature B cells and transforming events were identified....
 Christophe Fermé. September 2023, page 21

Epidemiology of classical Hodgkin lymphoma

Classical Hodgkin lymphoma is a rare neoplasia but represents one of the most common cancers in adults younger than 40 years old. Epidemiology of Hodgkin lymphoma remains fascinating with specific...
 Hervé Ghesquières. September 2023, page 25

A better understanding of biological mechanisms

 Hervé Ghesquières. September 2023, page 29

Diagnosis and staging of Hodgkin lymphoma

Hodgkin lymphoma (HL) is composed of two distinct disease entities: classical HL (cHL) and nodular lymphocyte predominant HL (NLPHL). NLPHL is a rare entity with a specific therapeutic management....
 Hervé Ghesquières. September 2023, page 31

Positron emission tomography: a central role in assessment and evaluation

 Salim Kanoun. September 2023, page 35

Frontline therapy for classical Hodgkin lymphoma patients

Upfront first-line chemotherapy is indicated for all features of classical Hodgkin's lymphoma, followed by involved node radiotherapy in early stages; the ABVD protocol (doxorubicin (Adriamycin),...
 Cédric Rossi, Olivier Casasnovas. September 2023, page 39

Relapse of Hodgkin lymphoma: second and subsequent line treatments

Patients who fail first-line treatment can be cured with salvage chemotherapy followed by intensified therapy and hematopoietic stem cell autotransplantation. This treatment strategy is feasible...
 Bénédicte Deau Fischer. September 2023, page 48

Challenges of long-term follow up for Hodgkin lymphoma survivors

Challenge of Hodgkin lymphoma care is to obtain a high level of curability and minimize acute toxicities and long-term complications of chemotherapy and radiotherapy. A specific long-term...
 Hervé Ghesquières. September 2023, page 53

Toxicity of targeted therapies and immunotherapy with checkpointinhibitors in Hodgkin lymphoma

In patients at increased risk of recurrence or progression after autotransplantation, or in cases of relapse after autotransplantation or after at least two lines of treatment when intensive...
 Jean-Marie Michot, Julien Lazarovici. September 2023, page 58

Fertility and gonadal disorders in patients with Hodgkin lymphoma

 Christine Rousset-Jablonski. September 2023, page 69

Hodgkin lymphoma: 10 key messages

 Hervé Ghesquières. September 2023, page 73